Literature DB >> 25568263

Obliteration of the medullary canal in an atypical bisphosphonate-related femoral fracture.

Derek T Cawley1, Helen L Barrett1, Paul Harrington1.   

Abstract

We present a case of a patient with a bisphosphonate-related atypical femoral fracture. Her surgical management was complicated by obliteration of the medullary canal, which prohibited the passage of an intramedullary nail. The relevant literature is discussed. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25568263      PMCID： PMC4289787          DOI： 10.1136/bcr-2014-205439

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  13 in total

1.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

2.  Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.

Authors:  R N Thompson; J R A Phillips; S H J McCauley; J R M Elliott; C G Moran
Journal:  J Bone Joint Surg Br       Date:  2012-03

3.  A rational approach to management of alendronate-related subtrochanteric fractures.

Authors:  S Das De; T Setiobudi; L Shen; S Das De
Journal:  J Bone Joint Surg Br       Date:  2010-05

4.  An atypical subtrochanteric femoral fracture from pycnodysostosis: a lesson from nature.

Authors:  Christopher J Yates; Miriam J Bartlett; Peter R Ebeling
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

5.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

6.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

7.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

9.  Fractures of the femur treated by open and closed intramedullary nailing using the fluted rod.

Authors:  M C Harper
Journal:  J Bone Joint Surg Am       Date:  1985-06       Impact factor: 5.284

10.  Denosumab and atypical femoral fractures.

Authors:  Per Aspenberg
Journal:  Acta Orthop       Date:  2013-10-31       Impact factor: 3.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.